Thus, we may hypothesize that the upregulation of ASM activity might confer the sensitivity of HCC towards locoregional antiproliferative treatments, such as mitomycin, with the latter being already clinically in use within TACE formulations. The gene discussed is SMPD1; the disease is hepatocellular carcinoma.